Nils Matzen

Company: NiSiPharm GmbH

Following his university studies of microbiology/biochemistry (Dipl.-Biol., Kiel) and PhD thesis (laboratory work in Coventy/UK; Dr. rer. nat., Kiel), Nils started his professional career 1982 at SmithKline, later GSK. After several management functions in regulatory affairs, clinical research, medical information, product management, and sales management, he became vice president commercial operations and managing director marketing. During this time, and under his responsibility, the GSK vaccines business in Germany was established, and reached sales of >250 mio € in 2003.

In 2004 Nils changed to Chiron/Novartis Vaccines and Diagnostics, where he was Vice President Commercial Operations for Central Europe, and where he grew the business from 98 mio € to 320 mio € by the end of 2007.

2008 he founded, together with Dr. Silke Sittner, his own company, NiSiPharm GmbH, offering his know-how in the commercialization of pharmaceutical/biotech products as a consultant, or as an interim manager, respectively, to the pharmaceutical and biotech industry.

His operational, executive experience includes general management, local, European and global marketing and sales management, merger/acquisition and business development, global launch projects, and health policy/market access in EU. Examples of NiSiPharm service assignments are, e.g., management functions in commercial operations (respiratory, HIV, oncology, vaccines, generics), market evaluation and recommendations to establish German businesses of foreign pharma, diagnostic, and medical devices companies, pharmapolitical projects, or the commercial evaluation and business planning of a new biological compound after phase 2 of the clinical development for a venture capital fund. During his professional life, Nils has initiated, and was involved in, numerous due diligence processes, he is experienced in vendor, as well as buyside due diligence, and is going to contribute insights and learnings from his real cases.